The tariff incentive: Similar to other recent drug pricing deals between the administration and pharma companies, Novo and Lilly will get a three-year tariff reprieve, as long as they commit to making more of their products in the US, and have secured FDA priority review vouchers for their oral weight loss treatments
In addition to being a glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide is also a glucose-dependent insulinotropic polypeptide (GIP) receptor
In the one human trial studying oral BPC-157 for inflammatory bowel disease, approximately 8% reported mild GI symptoms compared to 6% on placebo (Klicek et al., 2012)
Tirzepatide injections require specific temperature management to maintain their therapeutic potency and safety profile
and although GSH inhibits production of most inflammatory cytokines, it is needed to keep an adequate interferon gamma production by dendritic cells, essential for intracellular pathogen host defense (Ghezzi, 2011